Loading...
Market
Will Regenxbio announce additional positive results for RGX-202 by mid-2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Regenxbio's official press releases or clinical trial registries
Story
Regenxbio's RGX-202 Gene Therapy Shows Positive Results, FDA Approval Pathway Available
Nov 18, 2024, 12:34 PM
Regenxbio has reported promising results from its experimental gene therapy, RGX-202, for treating boys with Duchenne muscular dystrophy. The company presented clinical evidence showing improved muscle function in patients following the treatment. Regenxbio's CEO, Curran Simpson, indicated in an interview with STAT on Sunday that the FDA has communicated that the accelerated approval pathway remains available for this therapy. The positive data from a small trial is expected to support Regenxbio's pursuit of regulatory approval.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Meets primary endpoint • 25%
Fails primary endpoint • 25%
Mixed results • 25%
Trial not completed by end of 2025 • 25%
Yes • 50%
No • 50%
Primary endpoint met with significant improvement • 25%
Primary endpoint met with moderate improvement • 25%
Primary endpoint not met • 25%
Trial inconclusive or delayed • 25%
Highly positive • 25%
Moderately positive • 25%
Neutral • 25%
Negative • 25%
Complete Response (CR) • 25%
Partial Response (PR) • 25%
Stable Disease (SD) • 25%
Progressive Disease (PD) • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%